Goldman Sachs analyst Salveen Richter upgraded Adaptive Biotechnologies (ADPT) to Buy from Neutral with a $9 price target Since October 2024, ...

Goldman Sachs analyst Salveen Richter downgraded Intellia Therapeutics (NTLA) to Sell from Neutral with a price target of $9, down from $12, following the Q4 report. The firm awaits the Phase 3 ...

Salveen Richter, Goldman Sachs lead US biotech analyst for global investment research, joins Market Domination with Josh Lipton and Julie Hyman to discuss the impact of tariffs on the biotech sector.

Goldman Sachs analyst Salveen Richter initiated coverage of the company’s stock with a “Buy” rating and a price objective of $42. As per the analyst, Summit Therapeutics Inc. (NASDAQ ...

The latest guidance reduction was the second time in the last six months that the firm has revised its forecast in a negative direction, according to Goldman analyst Salveen Richter. Consequently ...

Salveen Richter, Goldman Sachs, inquired about external business development (BD). CEO Viehbacher highlighted that Biogen is actively exploring BD opportunities to enhance its pipeline ...

Salveen Richter; Analyst; Goldman Sachs Group, Inc. Yigal Nochomovitz; Analyst; Citigroup Inc. Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis ...

Salveen Richter, Goldman Sachs lead US biotech analyst for global investment research, joins Market Domination with Josh Lipton and Julie Hyman to discuss the impact of tariffs on the biotech sector.

Salveen Richter; Analyst; Goldman Sachs Group, Inc. Yigal Nochomovitz; Analyst; Citigroup Inc. Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis Pharmaceuticals ...